Insightec has received Singapore’s Health Sciences Authority (HSA) approval for its Exablate Neuro platform to precisely ablate tissue deep within the brain.

Also called Exablate 4000, the platform leverages MR guided Focused Ultrasound technology, where focused sound waves are safely guided by MRI to deliver treatment.

Exablate can be used to treat Essential Tremor in patients aged 22 years or above, or Tremor-dominant Parkinson’s Disease in patients aged 30 years or above, who are not responsive to medications.

Insightec CEO and board of directors chairman Maurice Ferré said: “The value of Focused Ultrasound for medical centres treating movement disorders is greatly improved patient care.

“Our technology enables patients to go from a life dominated by tremor to the potential for a calm, steady hand.”

Insightec is an Israeli medical device company engaged in harnessing the therapeutic power of acoustic energy.

The company claimed that 81 medical centres worldwide have established Focused Ultrasound programmes with its Exablate Neuro platform.

Also, it is working with Transmedic Group, a distributor of advanced medical technology in Southeast Asia, to advance the adoption of its Exablate Neuro in the Singapore market.

Transmedic managing director Teo Kee Meng said: “We are excited to bring this transformational technology to medical centres in Singapore. More importantly, patients will now have the option to choose a treatment that is outpatient and incisionless.”

In a separate development, Insightec announced that Samsung Medical Centre in South Korea is adopting its Exablate Neuro platform to establish Focused Ultrasound programme.

In February this year, the company has secured market approval from the Brazilian Health Regulatory Agency, ANVISA, and partnered with Strattner to debut its Focused Ultrasound technology in the Brazilian market.